Poly(ADP-Ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: ASCO Guideline Rapid Recommendation Update

被引：58
|
作者：
Tew, William P. [1 ]
Lacchetti, Christina [2 ]
Kohn, Elise C. [3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Amer Soc Clin Oncol, 2318 Mill Rd,Suite 800, Alexandria, VA 22314 USA
[3] NCI, Bethesda, MD 20892 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 33期
关键词：
D O I：
10.1200/JCO.22.01934
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline recommendations as a response to the emergence of new and practice-changing data. The rapid updates are supported by an evidence review and follow the guideline development processes outlined in the ASCO Guideline Methodology Manual. The goal of these articles is to disseminate updated recommendations, in a timely manner, to better inform health practitioners and the public on the best available cancer care options.
引用
收藏
页码：3878 / +
页数：7
相关论文
共 50 条
  • [1] Poly (ADP-ribose) polymerase inhibitors in the management of ovarian cancer
    Markman, Maurie
    WOMENS HEALTH, 2018, 14 : 1 - 6
  • [2] Update on poly(ADP-ribose) polymerase inhibitors resistance in ovarian cancer
    Dong, Ruihong
    Ding, Ting
    Li, Zhengyu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer
    Liu, Chia-Hao
    Chang, Yi
    Wang, Peng-Hui
    TAIWANESE JOURNAL OF OBSTETRICS & GYNECOLOGY, 2017, 56 (05): : 713 - 714
  • [4] Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations
    Xu, Qin
    Li, Zhengyu
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [5] Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
    Boussios, Stergios
    Abson, Charlotte
    Moschetta, Michele
    Rassy, Elie
    Karathanasi, Afroditi
    Bhat, Tahir
    Ghumman, Faisal
    Sheriff, Matin
    Pavlidis, Nicholas
    DRUGS IN R&D, 2020, 20 (02) : 55 - 73
  • [6] Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer
    Wiggans, Alison J.
    Cass, Gemma K. S.
    Bryant, Andrew
    Lawrie, Theresa A.
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (05):
  • [7] Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond
    Stergios Boussios
    Charlotte Abson
    Michele Moschetta
    Elie Rassy
    Afroditi Karathanasi
    Tahir Bhat
    Faisal Ghumman
    Matin Sheriff
    Nicholas Pavlidis
    Drugs in R&D, 2020, 20 : 55 - 73
  • [8] Inhibition of Poly ADP-Ribose Glycohydrolase Sensitizes Ovarian Cancer Cells to Poly ADP-Ribose Polymerase Inhibitors and Platinum Agents
    Matanes, Emad
    Lopez-Ozuna, Vanessa M.
    Octeau, David
    Baloch, Tahira
    Racovitan, Florentin
    Dhillon, Amandeep Kaur
    Kessous, Roy
    Raban, Oded
    Kogan, Liron
    Salvador, Shannon
    Lau, Susie
    Gotlieb, Walter H.
    Yasmeen, Amber
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] Poly(ADP-Ribose) Polymerase Inhibitors
    Garon, Edward B.
    Dubnett, Steven M.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S455 - S456
  • [10] SYSTEMATIC REVIEW OF POLY (ADP-RIBOSE) POLYMERASE INHIBITORS FOR TREATMENT OF OVARIAN CANCER
    Menges, B.
    Deitelzweig, C.
    Lin, J.
    Lingohr-Smith, M.
    Lin, G.
    VALUE IN HEALTH, 2018, 21 : S18 - S18
12345